The use of single signal anergy to inactive pathological B cells in an antigen-specific manner is discussed. Cross-linking surface immunoglobulin, with a construct which contains oligo valent B cell epitopes on a non-immunogenic molecular framework can be used to inac tivate the target B cells if the construct lacks T cells epitopes. An example of such a B cell toleragen is LJP 394, which inactivates anti-dsDNA-specific B cells in vivo in murine immu nized and spontaneous disease models. The drug enhances survival and lowers renal pathol ogy in BXSB mice. Appropriate definition of epitopes of pathological (auto) antibodies thus offers an opportunity for pharmacological intervention.
Goodnow CC et al. Induction of self-tolerance in mature peripheral B lymphocytes . Nature1989; 342: 385-391.
2.
Fulcher DA, Basten, A.Reduced lifespan of anergic self-reactive B cells in a double transgenic model . J Exp Med1994; 179: 125-134.
3.
Rammensee HG , Friede T., Stevanovic S.MHC ligands and peptide motifs: first listing . Immunogenetics1995 ; 41: 178-228.
4.
Parry S., Hasbold J., Holman M., Klaus GBHypercross-linking of surface IgM or IgD receptors on mature B cells induces apoptosis that is reversed by costimulation with IL-4 and anti-CD40 . J Immunol1994; 152: 2821-2829.
5.
Finkelman FD , Holmes JM, Dukhanina OI, Morris SCCross linking of membrane immunoglobulin D, in the absence of T cell help, kills mature B cells in vivo. J Exp Med1995; 181: 515-525.
6.
Lambert PH, Dixon FJPathogenesis of the glomerulonephritis of NZB/NZW mice. J Exp Med1968; 127: 507-521.
7.
Hahn B., Ebling FMSuppression of murine lupus nephritis by administration of an anti-idiotypic antibody to anti-DNA. J Immunol1984; 132: 187-190.
8.
McNeill HP, Simpson RJ, Chesterman CN, Krilis SAAntiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2glycoprotein I (apolipoprotein H). Proc Natl Acad Sci, USA1990; 87: 4120-4124.
9.
Matsuura E. et al. Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor. J Immunol1992; 148: 3885-3891.
10.
Lindstrom J. , Shelton D., Fujii Y.Myasthenia gravis. Adv Immunol1988; 42: 233-284.
11.
Marion S., Braun JM, Ropars A., Kohn LD, Charreire J.Induction of autoimmunity by immunization of mice with human thyrotropin receptor . Cell Immunol1994; 158: 329-341.
12.
Moise, KJ Jr. Management of red cell alloimmunization in pregnancy. In RA Sacher and ME Brecher (eds) Obstetric Transfusion Practice. Bethesda, MD: American Association of Blood Banks, 1993 ; 21-46.
13.
Jones DS et al. Immunospecific reduction of antioligonucleotide antibody-forming cells with a tetrakis-oligonucleotide conjugate (LJP 394), a therapeutic candidate for the treatment of lupus nephritis. J Med Chem1995; 38: 2138-2144.
